The final, formatted version of the article will be published soon.
REVIEW article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 15 - 2024 |
doi: 10.3389/fimmu.2024.1480701
This article is part of the Research Topic Epigenetic Regulation and Metabolism in the Tumor Microenvironment View all articles
TEAD transcription factor family emerges as a promising therapeutic target for oral squamous cell carcinoma
Provisionally accepted
Shuang Wang
1,2
Dan Shao
3*
Xiaoyan Gao
4*
Peng Zhao
1*
Fanzhi Kong
1*
Jiawei Deng
1*
Lianzhu Yang
1*
Wei Shang
5
Yaping Sun
1*
Zhiguang Fu
6*- 1 Qingdao Huangdao District Central Hospital, Qingdao, China
- 2 Qingdao Huanghai University, Qingdao, Shandong Province, China
- 3 Qingdao Stomatological Hospital, Qingdao, Shandong Province, China
- 4 Traditional Chinese Medical Hospital of Huangdao District, Qingdao, Shandong Province, China
- 5 The Affiliated Hospital of Qingdao University, Qingdao, Shandong Province, China
- 6 Air Force Medical Center, PLA, Beijing, China
The treatment of oral squamous cell carcinoma (OSCC) remains a significant difficulty, as there has been no improvement in survival rates over the past fifty years.Hence, exploration and confirmation of new dependable treatment targets and biomarkers is imperative for OSCC therapy. TEAD transcription factors are crucial for integrating and coordinating multiple signaling pathways that are essential for embryonic development, organ formation, and tissue homeostasis. In addition, by attaching to coactivators, TEAD modifies the expression of genes such as Cyr61, Myc, and connective tissue growth factor, hence facilitating tumor progression. Therefore, TEAD is regarded as an effective predictive biomarker due to its significant connection with clinical parameters in several malignant tumors, including OSCC.The efficacy of existing drugs that specifically target TEAD has demonstrated encouraging outcomes, indicating its potential as an optimal target for OSCC treatment. This review provides an overview of current targeted therapy strategies for OSCC by highlighting the transcription mechanism and involvement of TEAD in oncogenic signaling pathways. Finally, the feasibility of utilizing TEAD as an innovative approach to address OSCC and its potential clinical applications were analyzed and discussed.
Keywords: TEA Domain Transcription Factors, Hippo signaling pathway, oral squamous cell carcinoma, Molecular Targeted Therapy, biomarkers
Received: 14 Aug 2024; Accepted: 17 Sep 2024.
Copyright: © 2024 Wang, Shao, Gao, Zhao, Kong, Deng, Yang, Shang, Sun and Fu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Dan Shao, Qingdao Stomatological Hospital, Qingdao, 266001, Shandong Province, China
Xiaoyan Gao, Traditional Chinese Medical Hospital of Huangdao District, Qingdao, Shandong Province, China
Peng Zhao, Qingdao Huangdao District Central Hospital, Qingdao, China
Fanzhi Kong, Qingdao Huangdao District Central Hospital, Qingdao, China
Jiawei Deng, Qingdao Huangdao District Central Hospital, Qingdao, China
Lianzhu Yang, Qingdao Huangdao District Central Hospital, Qingdao, China
Yaping Sun, Qingdao Huangdao District Central Hospital, Qingdao, China
Zhiguang Fu, Air Force Medical Center, PLA, Beijing, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.